FI97139C - Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu - Google Patents

Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu Download PDF

Info

Publication number
FI97139C
FI97139C FI880017A FI880017A FI97139C FI 97139 C FI97139 C FI 97139C FI 880017 A FI880017 A FI 880017A FI 880017 A FI880017 A FI 880017A FI 97139 C FI97139 C FI 97139C
Authority
FI
Finland
Prior art keywords
psti
asp
thr
tyr
ile
Prior art date
Application number
FI880017A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI880017A0 (fi
FI97139B (fi
FI880017L (fi
Inventor
Wolfgang Bruns
Ronald Frank
Helmut Bloecker
John Collins
Friedhelm Maywald
Hans Fritz
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of FI880017A0 publication Critical patent/FI880017A0/fi
Publication of FI880017L publication Critical patent/FI880017L/fi
Application granted granted Critical
Publication of FI97139B publication Critical patent/FI97139B/fi
Publication of FI97139C publication Critical patent/FI97139C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI880017A 1987-01-07 1988-01-05 Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu FI97139C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB08700204A GB2199582A (en) 1987-01-07 1987-01-07 Analogues of pancreatic secretory trypsin inhibitor
GB8700204 1987-01-07

Publications (4)

Publication Number Publication Date
FI880017A0 FI880017A0 (fi) 1988-01-05
FI880017L FI880017L (fi) 1988-07-08
FI97139B FI97139B (fi) 1996-07-15
FI97139C true FI97139C (fi) 1996-10-25

Family

ID=10610323

Family Applications (1)

Application Number Title Priority Date Filing Date
FI880017A FI97139C (fi) 1987-01-07 1988-01-05 Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu

Country Status (15)

Country Link
US (1) US5126322A (da)
EP (1) EP0278112B1 (da)
JP (2) JPS63169994A (da)
KR (1) KR960010949B1 (da)
CN (1) CN1030999C (da)
AT (1) ATE97421T1 (da)
AU (1) AU592486B2 (da)
DE (1) DE3788216D1 (da)
DK (1) DK3688A (da)
ES (1) ES2059356T3 (da)
FI (1) FI97139C (da)
GB (1) GB2199582A (da)
HU (1) HUT46068A (da)
IL (1) IL85020A (da)
ZA (1) ZA8860B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0329693A4 (en) * 1986-10-30 1989-09-26 Synergen Biolog Inc HUMAN PANCREAS SECRETIONAL TRYPSIN INHIBITORS, MANUFACTURED BY DNA RECOMBINATION METHODS AND METHOD FOR THEIR PRODUCTION.
JPS6427473A (en) * 1987-07-23 1989-01-30 Mochida Pharm Co Ltd Human pancreas-secreting trypsin inhibitor and production thereof
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
DE58907373D1 (de) * 1988-03-07 1994-05-11 Ciba Geigy Modifizierte Proteine.
US5180667A (en) * 1988-03-07 1993-01-19 Ciba-Geigy Corporation Genes encoding eglin C mutants
JPH07102137B2 (ja) * 1988-07-19 1995-11-08 塩野義製薬株式会社 修飾ヒトｐｓｔｉ
DE3907492A1 (de) * 1989-03-08 1990-09-13 Biotechnolog Forschung Gmbh Verfahren zur isolierung und reinigung von hpsti und hpsti-varianten
US5231010A (en) * 1989-09-13 1993-07-27 Bayer Aktiengesellschaft Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
IL104314A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
EP0699750A1 (en) * 1994-06-07 1996-03-06 Gesellschaft für biotechnologische Forschung mbH (GBF) A collection of phagemids, a collection of Escherichia coli cells carrying the phagemids, a collection of phagemid particles produced from said collection and phagemid particles obtained according to the process
US6703201B1 (en) 1995-10-27 2004-03-09 Sagami Chemical Research Center Human PEC-60-like protein and DNA encoding this protein
JPH09124698A (ja) 1995-10-27 1997-05-13 Sagami Chem Res Center ヒトｐｅｃ−６０様蛋白質およびそれをコードするｄｎａ
US5851987A (en) * 1997-04-14 1998-12-22 Incyte Pharmaceuticals, Inc. Human tumor-associated Kazal inhibitor-like polypeptides and encoding polynucleotides
WO2008052238A1 (en) * 2006-11-01 2008-05-08 The University Of Sydney Treatment of urological cancer
EP2109457B1 (en) * 2007-02-12 2016-01-06 CSL Behring GmbH Therapeutic application of kazal-type serine protease inhibitors
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
JP6685925B2 (ja) 2014-04-17 2020-04-22 シンセティック バイオロジクス，インコーポレイテッド 治療用として改善された特性を有するβ−ラクタマーゼ
JP6803328B2 (ja) 2014-08-28 2021-01-06 シンセティック バイオロジクス，インコーポレイテッド 大腸菌ベースでのベータラクタマーゼ生産
KR102467968B1 (ko) 2014-10-08 2022-11-16 신세틱 바이오로직스, 인코퍼레이티드 베타-락타마제 제형 및 이의 용도
WO2016105498A1 (en) 2014-12-23 2016-06-30 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
EP3261662B1 (en) 2015-02-23 2021-07-21 Synthetic Biologics Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
AU2016229976B2 (en) 2015-03-06 2021-11-11 Theriva Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
WO2020176637A1 (en) 2019-02-26 2020-09-03 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2701890C2 (de) * 1977-01-19 1983-08-04 Hoechst Ag, 6230 Frankfurt Peptielischer Glycosidhydrolase-Inhibitor aus einem Streptomyceten und seine Verwendung
AU560584B2 (en) * 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
DE3429430A1 (de) * 1984-08-10 1986-02-20 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens
HU204563B (en) * 1984-12-06 1992-01-28 Synergen Biolog Inc Process for producing recombinant serine-protease inhibitors and dns sequencyes for them
US4760130A (en) * 1984-12-06 1988-07-26 Synergen Biologicals, Inc. Serine protease inhibitors and methods for isolation of same
JPH0616716B2 (ja) * 1986-10-14 1994-03-09 塩野義製薬株式会社 酵母におけるヒトｐｓｔｉの製造法
CA1339736C (en) * 1986-10-14 1998-03-17 Shionogi & Co., Ltd. Method for preparing fusion proteins
EP0329693A4 (en) * 1986-10-30 1989-09-26 Synergen Biolog Inc HUMAN PANCREAS SECRETIONAL TRYPSIN INHIBITORS, MANUFACTURED BY DNA RECOMBINATION METHODS AND METHOD FOR THEIR PRODUCTION.

Also Published As

Publication number Publication date
DK3688A (da) 1988-07-08
EP0278112A3 (en) 1990-01-10
CN88100146A (zh) 1988-08-31
ATE97421T1 (de) 1993-12-15
KR880009125A (ko) 1988-09-14
EP0278112B1 (de) 1993-11-18
ES2059356T3 (es) 1994-11-16
ZA8860B (en) 1988-10-26
AU592486B2 (en) 1990-01-11
EP0278112A2 (de) 1988-08-17
US5126322A (en) 1992-06-30
JPS63169994A (ja) 1988-07-13
GB8700204D0 (en) 1987-02-11
DE3788216D1 (de) 1993-12-23
AU1003888A (en) 1988-09-01
FI880017A0 (fi) 1988-01-05
IL85020A (en) 1993-02-21
IL85020A0 (en) 1988-06-30
FI97139B (fi) 1996-07-15
FI880017L (fi) 1988-07-08
GB2199582A (en) 1988-07-13
DK3688D0 (da) 1988-01-06
HUT46068A (en) 1988-09-28
JPH10117786A (ja) 1998-05-12
CN1030999C (zh) 1996-02-14
KR960010949B1 (ko) 1996-08-14

Similar Documents

Publication Publication Date Title
FI97139B (fi) Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu
AU604953B2 (en) Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology, process, expression vector and recombinant host therefor and pharmaceutical use thereof
CA2074943C (en) Process for the enzymatic cleavage of recombinant proteins using iga proteases
JPH08507695A (ja) Ｅｇ ▲ｉｉｉ▼セルラーゼの精製及び分子クローニング
FI108943B (fi) Menetelmiä seriiniproteaasi-inhibiittorien valmistamiseksi ja menetelmässä käytettävä synteettinen tai eristetty DNA-sekvenssi, yhdistelmävektori sekä bakteeri- tai hiivaisäntäsolu
CA1326216C (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
WO1994004697A1 (fr) Nouveau derive d'elafine
FI104724B (fi) Menetelmä aprotiniinivarianttien valmistamiseksi
JPH09512423A (ja) エラスターゼ阻害活性を有するα−１−アンチキモトリプシンアナログ
AU8172787A (en) Human pancreatic secretory trypsin inhibitors produced by recombinant dna methods and processes for the production of same
Auerswald et al. Recombinant leech-derived tryptase inhibitor: construction, production, protein chemical characterization and inhibition of HIV-1 replication
AU676019B2 (en) Novel peptide having esterase inhibitory activity and methodof producing same
EP1616007B1 (en) Inhibitor proteins of a protease and use thereof
WO1989001513A1 (fr) Prourokinase a action rapide
JP2657383B2 (ja) 新規な加水分解酵素とその製造方法
KR0134377B1 (ko) 에글린 b 및 에글린 c의 돌연변이체, 이를 암호화하는 dna 서열, 이러한 dna를 포함하는 재조합 벡터, 이러한 벡터로 형질전환된 숙주, 돌연변이체를 제조하는 방법 및 돌연변이체를 함유하는 약제학적 조성물
JPH01501037A (ja) 有機化合物の又はそれに関連する改良
US5231010A (en) Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
KR930003913B1 (ko) 트롬빈 억제 활성을 갖는 폴리펩티드 및 그의 제조방법
KR100379025B1 (ko) 짧은 바이오펩티드 제조용 디엔에이 카세트 및 이를 이용한 바이오펩티드의 제조 방법
JPH04258294A (ja) 分泌ベクター、該ベクターで形質転換した微生物及び該微生物から産生される産物の製造法
JPH1156365A (ja) 変異体ケクスタチン
JPH09503395A (ja) エリトリナ・カフラ由来の組換え阻害物質のセリンプロテアーゼ精製への使用
JP2683500C (da)
JPH04112791A (ja) トリプスタチン構造遺伝子及びその用途

Legal Events

Date Code Title Description
BB Publication of examined application
PC Transfer of assignment of patent

Owner name: GESELLSCHAFT FUER BIOTECHNOLOGISCHE

MM Patent lapsed

Owner name: GESELLSCHAFT FUER BIOTECHNOLOGISCHE FORSCHUNG MBH